Moore Capital Management LP Has $11.40 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Posted by Brenda Bartman on Jun 18th, 2026

Moore Capital Management LP increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 17.9% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 126,806 shares of the medical equipment provider’s stock after purchasing an additional 19,261 shares during the period. Moore Capital Management LP’s holdings in Zimmer Biomet were worth $11,402,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Dodge & Cox boosted its stake in Zimmer Biomet by 1.3% in the 4th quarter. Dodge & Cox now owns 23,506,849 shares of the medical equipment provider’s stock worth $2,113,736,000 after purchasing an additional 290,676 shares during the period. Vanguard Group Inc. boosted its stake in Zimmer Biomet by 0.8% in the 4th quarter. Vanguard Group Inc. now owns 23,483,741 shares of the medical equipment provider’s stock worth $2,111,658,000 after purchasing an additional 192,517 shares during the period. State Street Corp boosted its stake in Zimmer Biomet by 2.3% in the 4th quarter. State Street Corp now owns 8,826,974 shares of the medical equipment provider’s stock worth $795,814,000 after purchasing an additional 195,214 shares during the period. Capital International Investors boosted its stake in Zimmer Biomet by 11.5% in the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock worth $743,749,000 after purchasing an additional 778,467 shares during the period. Finally, Franklin Resources Inc. boosted its stake in Zimmer Biomet by 43.2% in the 4th quarter. Franklin Resources Inc. now owns 6,685,987 shares of the medical equipment provider’s stock worth $601,204,000 after purchasing an additional 2,017,857 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Upgrades and Downgrades

ZBH has been the subject of a number of research analyst reports. Wells Fargo & Company cut their target price on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Barclays cut their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a research report on Wednesday, April 29th. Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Leerink Partners initiated coverage on shares of Zimmer Biomet in a research report on Monday, April 13th. They issued a “hold” rating and a $101.00 target price for the company. Finally, BTIG Research reiterated a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $102.70.

Get Our Latest Research Report on ZBH

Insider Buying and Selling at Zimmer Biomet

In other news, insider Sang Yi sold 5,000 shares of the firm’s stock in a transaction on Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares in the company, valued at approximately $2,252,022.64. This trade represents a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Down 2.4%

Zimmer Biomet stock opened at $87.17 on Thursday. The company has a market capitalization of $16.86 billion, a P/E ratio of 22.64, a P/E/G ratio of 2.63 and a beta of 0.47. The firm’s fifty day simple moving average is $87.40 and its 200-day simple moving average is $90.21. The company has a current ratio of 1.73, a quick ratio of 0.95 and a debt-to-equity ratio of 0.50. Zimmer Biomet Holdings, Inc. has a 1-year low of $79.12 and a 1-year high of $108.29.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last released its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.86 by $0.23. The business had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.07 billion. Zimmer Biomet had a net margin of 9.05% and a return on equity of 13.24%. Zimmer Biomet’s revenue for the quarter was up 9.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Thursday, June 25th will be issued a dividend of $0.24 per share. The ex-dividend date is Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 24.94%.

About Zimmer Biomet

(Free Report)

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.